Vatorsecurities.se använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.

Equity Research

 

Commissioned research by Vator Securities is offered to selected life science companies – “By Invitation Only”

 

Commissioned research: Diamyd Medical

28 September 2020

As of September 15th, 2020, the company that was founded in 1984 delivered convincing top-line data – in line with medical consensus view of implementing precision medicine – consistently supporting positive effect of the first-in-class disease-modifying diabetes vaccine Diamyd® in a genetically defined group.

We initiate coverage with an Outperform rating. With a 50% LOA for the lead candidate Diamyd® and 18% LOA for Remygen® our risk-adjusted DCF valuation results in a value for Diamyd Medical of SEK 100 per share, corresponding to an equity value of approximately SEK 6.6 bn non diluted.